Dr. Justin Hay is a PK assessor at the UK’s Medicine and Healthcare Products Regulatory Agency (MHRA) and has been a member of the EMA’s Modelling and Simulation Working Party (MSWP). Prior to joining the MHRA, he worked in clinical drug development for 15 years. Dr Hay was conferred his PhD in Medicine (Pharmacology) from the University of Adelaide, Australia.
Dr. Nastya Kassir joined Certara (formerly Pharsight Corporation) in August 2008. She has applied PK and PK/PD modeling and simulation tools to drug development decisions across a range of therapeutic areas. Her expertise includes scientific and regulatory consultation on drug development programs for small and large molecules in various phases of drug development, particularly in pediatrics, orphan diseases and in the therapeutic areas of inflammation (rheumatoid arthritis, psoriasis, psoriatic arthritis) and oncology. Nastya has authored or co-authored more than 60 abstracts/manuscripts in the field of PK/PD. Dr. Kassir has a PharmD and has earned a PhD in Pharmaceutical Sciences from the University of Montreal, Faculty of Pharmacy and is a fellow of the American College of Clinical Pharmacology.